The MPSIVA rat model was essential to assess the efficacy and long-term durability of the AAV9-Galns gene therapy to treat the whole plethora of pathological alterations of MPSIVA disease, including skeletal system and cartilage alterations. Here, GALNS is linked to mucopolysaccharidosis type 4A.